Trial results

$LXRX — sotagliflozin

LEXICON PHARMACEUTICALS, INC. (LXRX) sotagliflozin: trial results in hypertrophic cardiomyopathy (HCM), 2027.

Research by Catalyst Intel

The catalyst

"Lexicon continues to expect topline results in the first quarter of 2027."

— Lexicon Pharmaceuticals, Inc., 8-K filed 2026-11-05 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

LXRX-SOTAGLIFLOZI-2026

Company

LEXICON PHARMACEUTICALS, INC.

Kind

Trial results

Indication

hypertrophic cardiomyopathy (HCM)

Window

2027-01-01 – 2027-12-31

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.